Patents by Inventor Shawn Wells

Shawn Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12257240
    Abstract: Among others, the present invention provides methods and compositions for controlling blood glucose or weight, including a combination of (i) a therapeutically effective amount of berberine (BBR), or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, including dihydroberberine (DHB); and (ii) vitamin B12. The combination effectively ameliorates BBR or DHB side effects, including VB12 reduction, gastrointestinal discomfort, and slowed bowel movements, by promoting transcobalamin II receptors synthesis, decreasing homocysteine levels and maintaining intestinal balance, including short chain fatty acids content, gut microbiota diversity and richness.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: March 25, 2025
    Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.
    Inventors: Shawn Wells, Ronghua Yi, Mingru Wang, Kylin Liao
  • Publication number: 20240074996
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Application
    Filed: July 21, 2023
    Publication date: March 7, 2024
    Applicant: Keto Innovations, LLC
    Inventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao, Christian Unger
  • Patent number: 11903932
    Abstract: The present invention provides novel methods for enhancing muscle function in a mammal, the method includes administration to the mammal of a composition comprising therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. The present invention also provides a composition including therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for enhancing muscle function. In addition, the present invention provides methods for preparing any compositions disclosed herein.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: February 20, 2024
    Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.
    Inventors: Mingru Wang, Ronghua Yi, Shawn Wells, Kylin Liao
  • Publication number: 20230364043
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Application
    Filed: May 17, 2023
    Publication date: November 16, 2023
    Applicant: Keto Innovations, LLC
    Inventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao, Christian Unger
  • Patent number: 11766416
    Abstract: Compositions of ?-aminoisobutyric acid (BAIBA), and methods of using the same to achieve a physiological objective, are provided. Compositions of BAIBA having enantiomeric purity, in which a selected proportion of the BAIBA is L-?-aminoisobutyric acid (L-BAIBA) and/or a selected proportion of the BAIBA is D-?-aminoisobutyric acid (D-BAIBA), are also provided.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: September 26, 2023
    Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.
    Inventors: Qilin Liao, Shawn Wells
  • Patent number: 11707465
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: July 25, 2023
    Assignee: Ortho-Nutra LLC
    Inventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20230149329
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 18, 2023
    Applicant: Keto Innovations, LLC
    Inventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao
  • Publication number: 20230147386
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Application
    Filed: August 9, 2022
    Publication date: May 11, 2023
    Applicant: Ortho-Nutra, LLC
    Inventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20230115966
    Abstract: The disclosed compositions, and methods relate to compositions for human consumption and comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 13, 2023
    Inventors: Shawn Wells, Ralf Jager, Kylin Liao, Martin Purpura
  • Patent number: 11534426
    Abstract: Among others, the present invention provides novel methods for extending lifespan or improving healthspan in a mammal, which include administration to the mammal of a composition containing a therapeutically effective amount of ergothioneine, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 27, 2022
    Assignee: Nanjing Nutrabuilding Bio-tech Co., Ltd.
    Inventors: Joseph L. Evans, Qiru Fan, Shawn Wells, Kylin Liao
  • Patent number: 11491141
    Abstract: Glutathione deficiencies and deficiencies in glutathione synthetase activity, and therapeutic methods for the treatment thereof.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: November 8, 2022
    Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.
    Inventors: Joseph L. Evans, Qiru Fan, Shawn Wells, Kylin Liao
  • Publication number: 20220331328
    Abstract: The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
    Type: Application
    Filed: April 7, 2022
    Publication date: October 20, 2022
    Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
  • Publication number: 20220305019
    Abstract: Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Martin Purpura, Ralf Jäger, Shawn Wells, Kylin Liao
  • Publication number: 20220305020
    Abstract: Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.
    Type: Application
    Filed: March 28, 2022
    Publication date: September 29, 2022
    Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
  • Patent number: 11426410
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 30, 2022
    Assignee: Ortho-Nutra, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20220249419
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 11, 2022
    Applicant: Keto Innovations, LLC
    Inventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao
  • Publication number: 20220202789
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 30, 2022
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells
  • Patent number: 11337945
    Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: May 24, 2022
    Assignee: Keto Innovations, LLC
    Inventors: Ryan P. Lowery, Shawn Wells, Jacob Wilson, Kylin Liao
  • Publication number: 20220054441
    Abstract: Compositions of ?-aminoisobutyric acid (BAIBA), and methods of using the same to achieve a physiological objective, are provided. Compositions of BAIBA having enantiomeric purity, in which a selected proportion of the BAIBA is L-?-aminoisobutyric acid (L-BAIBA) and/or a selected proportion of the BAIBA is D-?-aminoisobutyric acid (D-BAIBA), are also provided.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 24, 2022
    Inventors: Qilin Liao, Shawn Wells
  • Patent number: 11026991
    Abstract: The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Ingenious Ingredients, LP
    Inventors: Martin Purpura, Ralf Jaeger, Shawn Wells, Kylin Lao, Anton Fliri